⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory anaplastic large cell lymphoma

Every month we try and update this database with for refractory anaplastic large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaNCT00939770
Recurrent Child...
Recurrent Malig...
Recurrent Neuro...
Refractory Anap...
Refractory Mali...
Refractory Neur...
Crizotinib
Laboratory Biom...
Pharmacological...
Questionnaire A...
1 Year - 21 YearsChildren's Oncology Group
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaNCT03017820
B-Cell Non-Hodg...
Histiocytic and...
Myelodysplastic...
Previously Trea...
Recurrent Adult...
Recurrent Anapl...
Recurrent Angio...
Recurrent Mycos...
Recurrent Plasm...
Recurrent Prima...
Recurrent T-Cel...
Refractory Acut...
Refractory Anap...
Refractory Angi...
Refractory Myco...
Refractory Peri...
Refractory Plas...
Refractory Prim...
Refractory T-Ce...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Positron Emissi...
Recombinant Ves...
Single Photon E...
Cemiplimab
18 Years - Mayo Clinic
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNCT02978625
Adenoid Cystic ...
Adnexal Carcino...
Anaplastic Larg...
Anaplastic Larg...
Apocrine Carcin...
Cylindrocarcino...
Digital Papilla...
Endocrine Mucin...
Extramammary Pa...
Extraocular Cut...
Hidradenocarcin...
Keratoacanthoma
Malignant Sweat...
Merkel Cell Car...
Microcystic Adn...
NK-Cell Lymphom...
Papillary Adeno...
Porocarcinoma
Primary Cutaneo...
Recurrent Matur...
Recurrent T-Cel...
Refractory Anap...
Refractory Matu...
Refractory Merk...
Refractory Myco...
Refractory Prim...
Refractory Skin...
Refractory T-Ce...
Sezary Syndrome
Signet Ring Cel...
Skin Basal Cell...
Skin Basosquamo...
Skin Squamous C...
Spiradenocarcin...
Squamoid Eccrin...
Squamous Cell C...
Sweat Gland Car...
Trichilemmal Ca...
Vulvar Squamous...
Biopsy
Biospecimen Col...
Computed Tomogr...
Laboratory Biom...
Nivolumab
Positron Emissi...
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
Study of Pembrolizumab (MK-3475) in Combination With RomidepsinNCT03278782
Recurrent Anapl...
Recurrent Angio...
Recurrent Matur...
Recurrent Mycos...
Recurrent Prima...
Refractory Anap...
Refractory Angi...
Refractory Matu...
Refractory Myco...
Refractory Peri...
Refractory Prim...
Pembrolizumab
Romidepsin
18 Years - M.D. Anderson Cancer Center
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaNCT01590732
Mycosis Fungoid...
Recurrent Anapl...
Recurrent Angio...
Recurrent Enter...
Recurrent Hepat...
Recurrent Perip...
Refractory Anap...
Refractory Angi...
Refractory Ente...
Refractory Hepa...
Refractory Peri...
Carboplatin
Etoposide
Ifosfamide
Romidepsin
18 Years - M.D. Anderson Cancer Center
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaNCT00939770
Recurrent Child...
Recurrent Malig...
Recurrent Neuro...
Refractory Anap...
Refractory Mali...
Refractory Neur...
Crizotinib
Laboratory Biom...
Pharmacological...
Questionnaire A...
1 Year - 21 YearsChildren's Oncology Group
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasNCT04774068
Recurrent Anapl...
Recurrent Matur...
Recurrent Prima...
Recurrent Trans...
Refractory Anap...
Refractory Matu...
Refractory Prim...
Refractory Tran...
T-Cell Non-Hodg...
Parsaclisib
Romidepsin
18 Years - Ohio State University Comprehensive Cancer Center
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNCT02978625
Adenoid Cystic ...
Adnexal Carcino...
Anaplastic Larg...
Anaplastic Larg...
Apocrine Carcin...
Cylindrocarcino...
Digital Papilla...
Endocrine Mucin...
Extramammary Pa...
Extraocular Cut...
Hidradenocarcin...
Keratoacanthoma
Malignant Sweat...
Merkel Cell Car...
Microcystic Adn...
NK-Cell Lymphom...
Papillary Adeno...
Porocarcinoma
Primary Cutaneo...
Recurrent Matur...
Recurrent T-Cel...
Refractory Anap...
Refractory Matu...
Refractory Merk...
Refractory Myco...
Refractory Prim...
Refractory Skin...
Refractory T-Ce...
Sezary Syndrome
Signet Ring Cel...
Skin Basal Cell...
Skin Basosquamo...
Skin Squamous C...
Spiradenocarcin...
Squamoid Eccrin...
Squamous Cell C...
Sweat Gland Car...
Trichilemmal Ca...
Vulvar Squamous...
Biopsy
Biospecimen Col...
Computed Tomogr...
Laboratory Biom...
Nivolumab
Positron Emissi...
Talimogene Lahe...
18 Years - National Cancer Institute (NCI)
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaNCT03017820
B-Cell Non-Hodg...
Histiocytic and...
Myelodysplastic...
Previously Trea...
Recurrent Adult...
Recurrent Anapl...
Recurrent Angio...
Recurrent Mycos...
Recurrent Plasm...
Recurrent Prima...
Recurrent T-Cel...
Refractory Acut...
Refractory Anap...
Refractory Angi...
Refractory Myco...
Refractory Peri...
Refractory Plas...
Refractory Prim...
Refractory T-Ce...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Positron Emissi...
Recombinant Ves...
Single Photon E...
Cemiplimab
18 Years - Mayo Clinic
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasNCT03598998
Anaplastic Larg...
Nodal Periphera...
Recurrent Anapl...
Recurrent Angio...
Recurrent Enter...
Recurrent Folli...
Recurrent Hepat...
Recurrent Matur...
Recurrent Monom...
Recurrent Mycos...
Recurrent Perip...
Refractory Anap...
Refractory Angi...
Refractory Ente...
Refractory Foll...
Refractory Hepa...
Refractory Matu...
Refractory Myco...
Refractory Peri...
Subcutaneous Pa...
Pembrolizumab
Pralatrexate
18 Years - City of Hope Medical Center
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLNCT02572453
Recurrent Anapl...
Recurrent Diffu...
Recurrent Mantl...
Recurrent Trans...
Refractory Anap...
Refractory Diff...
Refractory Mant...
Refractory Tran...
Onalespib
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: